CD274 and non-small cell lung carcinoma: The efficacy of pembrolizumab in patients with PD-L1 positive (>1%) NSCLC with untreated or progressive asymptomatic brain metastases between 5 and 20 mm of diameter has also recently been tested in a phase II trial that reported a cerebral response rate of 33%.